Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen to Integrate Sample Prep Products into Artus Molecular Diagnostics

NEW YORK, Dec. 10 (GenomeWeb News) - Qiagen's German subsidiary has entered into a manufacturing and supply deal with Artus, of Hamburg, Germany in which Artus will integrate Qiagen's nucleic acid sample preparation products into its infectious disease diagnostic systems, the companies said today.

 

Under the agreement, Artus will use versions of Qiagen's QiAamp technology into its custom diagnostic tooks, which include systems for detection of diseases such as SARS, Herpes simplex virus -1/-2, EBV, West Nile Virus, Malaria, and Salmonella. The systems use Artus' RealArt technology, which is based on PCR technology that Artus has licensed from Roche, according to the companies.

 

The companies did not disclose the financial terms of the agreement.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.